- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Industry Optimism Outweighs Personal Job Security
Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed a mix of muted optimism and stagnant employment options.
Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed a mix of muted optimism and stagnant employment options. Readers of Pharmaceutical Technology shared their perspectives on the current employment situation in the magazine’s annual employment survey. The respondents represent a cross section of small- and large-molecule drug development functions from facilities in North America, Europe, and other locations. Approximately 60% of the respondents held advanced degrees, divided evenly between Master’s and doctorate degrees.
In 2013, more than half of the respondents said they were involved in a merger, acquisition, downsizing, or restructuring. This represents a significant jump from 2012, when 36.1% of survey participants experienced similar company changes. This activity could be a reason for the slight pullback in confidence in job security.
For the full results of Pharmaceutical Technology‘s 2013 employment survey, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
